Albumin binding cisplatin prodrug BTP-114

Drug Overview

Albumin binding cisplatin prodrug BTP-114 is a highly advanced, experimental cancer medicine. It is often referred to as a “Smart Drug” because it uses a targeted delivery system to bring chemotherapy directly to the tumor while trying to spare the rest of the body.

Currently, BTP-114 is an investigational drug. This means it is not yet available at your local pharmacy. It is actively being studied in clinical trials at major research hospitals. Doctors are testing it to see how well it fights advanced solid tumors, especially in patients who have specific genetic changes like BRCA mutations.

• Generic Name: Albumin binding cisplatin prodrug BTP-114 (often simply called BTP-114)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Platinum-based Antineoplastic / Prodrug / Targeted Delivery Agent
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA Approved. It is actively being evaluated in early-phase (Phase I and Phase II) clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how BTP-114 works, it helps to break down its name.

• Prodrug: This means the medicine is mostly inactive when it enters your body. It has to be processed by the body to turn “on.”
• Cisplatin: This is a very powerful, classic chemotherapy drug that kills cancer cells.
• Albumin binding: Albumin is the most common protein floating in your blood. It acts like a natural delivery truck carrying nutrients around the body.

At the molecular level, when BTP-114 is infused into the blood, it has a special chemical hook (a maleimide group) that immediately grabs onto the albumin protein. By riding on this albumin “truck,” the drug can circulate in the blood for a very long time—up to 10 days, compared to just a few hours for standard cisplatin.

Cancer tumors grow very fast and build messy, leaky blood vessels. Because albumin is a large molecule, it easily slips through these leaky vessels and gets trapped inside the tumor. This process is called the Enhanced Permeability and Retention (EPR) effect. Furthermore, starving cancer cells actively swallow albumin to use as food.

Once the albumin-drug combo is trapped inside the cancer cell, the active cisplatin is released. The cisplatin then enters the cell’s command center (the nucleus) and physically binds to the DNA. It creates strict chemical cross-links between the DNA strands. Because the DNA is glued together, the cancer cell cannot read its genetic code or divide. Realizing it is broken beyond repair, the cancer cell triggers its own death (a process called apoptosis).

FDA Approved Clinical Indications

Important Note: Because BTP-114 is an experimental medication, it does not currently have official FDA approvals for general public use. However, it is being actively tested in clinical trials for the following investigational oncological uses:

• Treatment of advanced solid tumors that carry DNA repair mutations (such as BRCA1 or BRCA2 mutations).
• Treatment of advanced ovarian cancer.
• Treatment of triple-negative breast cancer (TNBC).
• Treatment of advanced prostate and pancreatic cancers.

Non-oncological uses:

• None. This drug is strictly being studied for cancer treatment.

Dosage and Administration Protocols

Because BTP-114 is an investigational drug, the exact dosage is decided by strict clinical trial rules. Doctors are still establishing the absolute best dose, but the targeted delivery allows patients to safely tolerate higher amounts of the drug than standard cisplatin.

Dose Adjustments

• Renal Insufficiency (Kidney Issues): Standard cisplatin is very hard on the kidneys. Because BTP-114 stays attached to albumin, it is not filtered through the kidneys as quickly, which reduces kidney damage. However, patients with severe kidney problems may still require dose reductions or may be excluded from trials.
• Hepatic Insufficiency (Liver Issues): Patients with liver issues are monitored closely during trials. Severe liver problems may require trial doctors to lower the dose or pause the treatment.

Clinical Efficacy and Research Results

Recent clinical research between 2020 and 2025 has focused on proving that BTP-114 can deliver more medicine to the tumor with fewer side effects.

• Tumor Accumulation: Preclinical and early clinical trial data show a major success in drug delivery. BTP-114 leads to a 13-fold to 15-fold increase in the amount of platinum that actually reaches and stays inside the tumor compared to standard cisplatin.
• Targeted Success: The drug has shown the most promise in patients whose tumors have a hard time repairing DNA (such as those with BRCA mutations). In these specific groups, Phase I/II trials have shown improved rates of “stable disease” (stopping the tumor from growing) and partial tumor shrinkage.
• Disease Progression: While exact long-term survival rates are still being gathered in ongoing trials, the sustained release of the drug means it can constantly fight the tumor day and night, offering a longer period of tumor growth inhibition compared to older platinum drugs.

Safety Profile and Side Effects

Because BTP-114 is a targeted form of cisplatin, it shares similar side effects, though early studies suggest they are less severe because less of the drug leaks into healthy organs.

Black Box Warning

There is no specific FDA Black Box Warning for BTP-114 yet, as it is investigational. However, all platinum-based drugs usually carry warnings for severe kidney toxicity, nerve damage, and bone marrow suppression.

Common Side Effects (Occur in >10% of patients)

• Nausea and Vomiting: Very common with all platinum therapies.
• Fatigue: Feeling unusually tired or weak.
• Myelosuppression: Low white blood cell counts (increasing infection risk) and low red blood cell counts (anemia).
• Peripheral Neuropathy: Tingling, numbness, or pain in the fingers and toes.

Serious Adverse Events (Occur rarely)

• Nephrotoxicity: Serious damage to the kidneys.
• Ototoxicity: Ringing in the ears (tinnitus) or permanent hearing loss.
• Severe Allergic Reactions: Anaphylaxis during the IV infusion.

Side Effect Management Strategies

• For Nausea: Doctors will give you strong anti-nausea medications before the infusion begins and give you pills to take at home.
• For Kidney Protection: You will receive extra IV fluids before and after the drug is given to flush your kidneys. You must also drink lots of water at home.
• For Neuropathy: Tell your doctor immediately if your hands or feet feel numb. They may need to lower your dose to prevent permanent nerve damage.

Research Areas

BTP-114 is a major focus in the research area of personalized medicine and combination therapy. Because BTP-114 works exceptionally well in cancers with BRCA mutations, scientists are actively testing how to combine it with other targeted pills called PARP inhibitors (like olaparib). By using BTP-114 to break the cancer cell’s DNA, and using a PARP inhibitor to block the cell’s backup repair system, researchers hope to create a devastating “one-two punch” against tough-to-treat tumors. There is currently no significant research linking this drug to stem cell therapies.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

• Genetic Profiling: The tumor or your blood will be tested for BRCA mutations to see if you are a good candidate for the drug.
• Kidney Function Tests: Blood and urine tests to make sure your kidneys are strong enough to process the platinum.
• Complete Blood Count (CBC): To ensure you have enough healthy blood cells before starting.
• Hearing Test (Audiometry): To establish a baseline for your hearing, as platinum drugs can affect the ears.

Precautions During Treatment

• Infection Risk: Because the drug lowers your white blood cells, you will be at a higher risk of getting sick. Avoid crowded places and people who are ill.

Do’s and Don’ts

• DO ask your oncologist if you qualify for a clinical trial testing BTP-114, especially if you have a BRCA-mutated breast, ovarian, or prostate cancer.
• DO drink plenty of water (at least 8 to 10 glasses a day) for the first few days after your infusion to protect your kidneys.
• DO eat small, frequent meals if you feel sick to your stomach.
• DON’T ignore a fever over 100.4°F (38°C). Call your care team immediately, as this could be a sign of a dangerous infection.
• DON’T start any new vitamins or herbal supplements without telling your clinical trial team, as they might interact with the experimental drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, clinical trial eligibility, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.